16 Aug

Enterprise Products Partners and MPLX: Analysts’ Ratings

WRITTEN BY Rekha Khandelwal, CFA

Analysts’ recommendations

All of the analysts surveyed by Reuters covering Enterprise Products Partners (EPD) and MPLX (MPLX) are bullish on the stocks. All of the surveyed analysts have rated both of the stocks as a “buy.” In comparison, 79% of the analysts rated Williams Companies (WMB) as a “buy,” while 71% rated Kinder Morgan (KMI) as a “buy.”

Enterprise Products Partners and MPLX: Analysts’ Ratings

The median target price for Enterprise Products Partners is $33, which implies an upside potential of 15% from its current price of $28.74. Enterprise Products Partners saw upward revisions in its target price after its second-quarter results. To learn more, read Enterprise Products Partners Saw Higher Target Prices.

MPLX’s target price

The median target price for MPLX is $42, which implies an upside potential of 14% from its current price of $36.96. On July 27, Stifel raised its target price for MPLX from $42 to $44.

Enterprise Products Partners and MPLX’s strong distribution history, attractive yield, expected distribution growth, healthy coverage, strong earnings growth, planned projects, and conservative leverage likely contributed to analysts’ positive ratings for these stocks.

Kinder Morgan and Williams Companies

The median target price for Kinder Morgan is $21, which implies an upside potential of 18% from its current price of $17.73. Williams Companies’ median target price of $34 implies an upside potential of 13% from its current price of $30.0.

Latest articles

Tesla (TSLA) stock short sellers seem to be getting exasperated. Notably, Tesla stock has been the short sellers’ favorite.

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.